Natco Pharma Limited Valuation
NATCOPHARM · Healthcare · Current price ₹785.2
Is Natco Pharma Limited undervalued?
We estimate the fair value of Natco Pharma Limited at ₹1,468 per share, against a market price of ₹815. That puts the share price about +80.0% below our estimate, at low confidence. This is our view of what the business is worth, not a target price or a forecast of where the share price will go.
How this fair value is calculated
This estimate comes from 2 methods: Discounted cash flow (2-stage) (₹1,131), Fair multiple (P/E) (₹2,097). Each is weighted by how well its inputs held up for this company. The full working, including the assumptions and what data was missing, is set out below.
The range around this estimate
Our estimate for Natco Pharma Limited spans ₹1,131 to ₹2,097. That range is wide, which is the honest signal here: read the range rather than the single number. A margin of safety means buying meaningfully below the estimate: the wider the range, the more room the assumptions leave for error.
Valuation multiples
Natco Pharma Limited trades at a P/E of 9.9x and a P/B of 1.6x, with a dividend yield of 0.2%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.
How we got this fair value
Every number below is part of the same estimate for Natco Pharma Limited. Nothing here is a target price or a forecast of where the share price will go.
The inputs are thin or the models disagree sharply. This is our least reliable kind of estimate, so read the range rather than the single number.
Estimate range ₹1,131 – ₹2,097
Why this method for this business
DCF and relative PE are the most appropriate models for a pharmaceutical company with a strong moat and predictable cash flows. EV/EBITDA is excluded due to insufficient data quality.
The models behind the number
Each method is weighted by how well its inputs held up for this company.
Intrinsic value from 2-stage discounted cash flows (primary for asset-light / normal businesses); FCFE path
- ev_ebitda was excluded due to missing inputs and lack of reliable EBITDA data for normalization
What was missing
- Missing forward EBITDA estimates
- Limited analyst coverage for precise multiple normalization
What drives it
28 inputs, grouped by how strong each claim is
- FCF_0 (normalized)
- 862 ₹cr
- Net debt
- 714 ₹cr
- Sector-median P/E
- 38.26×
- Peers used
- 42
- EPS (TTM)
- 63.89 ₹/share
- Own-history median P/E
- 14.38×
fcf_norm (median ≤5y positive)
gross debt (cash n/a)
peer-median
peer-median
computed
reconstructed (one feature, dampened — not a cap)
- Discount rate (r)
- 13.28%
- Beta
- 0.85
COE (building-block)
bottom-up industry
- Stage-1 start growth
- 20%
- Fade shape
- linear
- Terminal growth (g)
- 5.39%
- Stage-1 years
- 10 y
pat_cagr_5y
lifecycle Growth
macro terminal × quality premium
lifecycle Growth horizon
- Lifecycle stage
- Growth
- Quality premium
- 1.078×
- Anchor correction
- peer anchor 38.3x diverges 0.4x from 7yr own-history 14.4x (no size-comparable peer) — anchor blended 0.6 toward own-history → 23.9x
- Term: quality
- +2.1%
- Term: growth
- +40.0%
- Term: capital_allocation
- -0.4%
- Term: financial_strength
- +8.2%
- Term: history
- -12.0%
- Term: sector_rerating
- +0.0%
- Term: rate_regime
- +1.2%
- Term: risk
- +0.0%
forecast engine (L20)
moat Narrow + capital allocation
peer-anchor mismatch — deep own-history used instead
quality 59/100 (high, stable returns) → premium
durable ~20% CAGR (ROCE 18% > hurdle) → premium
capital allocation: steady → neutral
financial strength: effectively debt-free → premium
history: market paid -40% vs sector, dampened ×0.3 (one feature, not the anchor)
sector re-rating: no sector-norm history → not used
rates: risk-free 6.9% below ~7.1% normal → higher multiple
risk: no analyst-dispersion signal available → neutral (lowers confidence, not PE)
- Path
- FCFE
- Terminal-value fraction
- 0.535
- Premium vs sector
- +37.2%
- Fair-multiple confidence
- 80%
- Fair P/E
- 32.82×
computed (D/E vs 0.8)
PV_TV / (PV_1+PV_TV)
fundamentals + macro (not capped at own history)
data completeness + term agreement
sector median × ∏(1+term) — Dynamic Fair Multiple
Who computed this
A language model (qwen3:8b) selects the valuation method and the judgement inputs for Natco Pharma Limited: which models suit the business, the moat, the growth and margin assumptions. It does not produce the number. The fair value itself is computed in Python by a deterministic engine (version 2026.08.1) from those inputs, so the same inputs always give the same result and every figure above can be traced to a source.
Estimated 14 Sept 2026. Re-run as new financials and news arrive.
How we value stocks
We estimate what a business is worth from its own economics: cash flows, returns on capital, and a multiple justified by its quality, rather than from where the share price has been. A fair value estimate is a view, not a verdict, and it is only as good as the inputs listed above.
Read the full fair-value methodologyUnderstand the ratios
More on Natco Pharma Limited
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.